Skip to main content

LENZ Therapeutics, Inc.

LENZ
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001815776

No open-market purchases or sales by LENZ Therapeutics, Inc. insiders were filed in the last 90 days; 145 institutions reported holding it in 13F filings for Q2 2026, worth $197.3M in total; no superinvestor holds it.

Q2 2021 vs. Q1 2021

How the institutions holding LENZ Therapeutics, Inc. changed between Q1 2021 and Q2 2021.

All holders in Q2 2021All holders in Q1 2021

13F holders of LENZ: Q1 2021 compared with Q2 2021
MeasureQ1 2021Q2 2021Change
Holders051+51
Shares032.2M+32.2M
Value$0$981.4M+$981.4M

New holders (51)

Institutions that held LENZ Therapeutics, Inc. at the end of Q2 2021 but not at the end of Q1 2021.

Institutions new to LENZ in Q2 2021
InstitutionSharesValue% of portfolio
Samsara BioCapital, LLC7,431,623$228.4M30.02%
FMR LLC3,761,979$110.6M0.01%
Ra Capital Management, L.P.2,698,369$82.9M1.33%
Rock Springs Capital Management LP2,151,738$66.1M1.31%
VR Adviser, LLC1,612,617$49.6M6.01%
Citadel Advisors LLC1,288,225$38.9M0.04%
Janus Henderson Group PLC1,251,005$36.7M0.02%
OrbiMed Advisors LLC1,106,307$34.0M0.35%
Logos Global Management LP1,070,762$32.9M2.82%
SB Management Ltd993,402$30.5M0.36%
Deerfield Management Company, L.P. (Series C)906,308$27.9M0.49%
Perceptive Advisors LLC875,093$26.9M0.35%
Avidity Partners Management LP735,500$22.6M0.61%
Board of Trustees of The Leland Stanford Junior University703,701$21.6M2.02%
Artal Group S.A.700,000$21.5M0.49%
Norges Bank700,000$21.5M0.00%
Federated Hermes, Inc.650,000$20.0M0.04%
Millennium Management LLC589,833$18.1M0.02%
UBS Asset Management Americas Inc393,787$12.1M0.01%
Woodline Partners LP309,723$9.52M0.18%
Jennison Associates LLC300,000$9.22M0.01%
Adage Capital Partners GP, L.L.C.300,000$9.22M0.02%
Goldman Sachs Group Inc274,426$8.43M0.00%
Morgan Stanley263,502$8.10M0.00%
Cormorant Asset Management, LP203,153$5.93M0.23%
Suvretta Capital Management, LLC125,000$3.84M0.06%
BlackRock Inc.103,581$3.18M0.00%
Blackstone Group Inc.75,000$2.31M0.01%
LMR Partners LLP70,000$2.15M0.03%
Monashee Investment Management LLC60,000$1.84M0.22%
Pinz Capital Management, LP52,543$1.61M0.49%
Asymmetry Capital Management, L.P.51,039$1.57M1.08%
Squarepoint Ops LLC40,000$1.23M0.01%
Caas Capital Management LP40,000$1.23M0.07%
Ghisallo Capital Management LLC40,000$1.23M0.05%
Marshall Wace North America L.P.36,646$1.13M0.00%
Alyeska Investment Group, L.P.30,000$922.0K0.01%
Vanguard Group Inc30,000$921.0K0.00%
Davidson Kempner Capital Management LP25,000$768.0K0.01%
Sphera Funds Management Ltd.24,957$767.0K0.07%
Voloridge Investment Management, LLC20,000$615.0K0.00%
Balyasny Asset Management LLC19,232$591.0K0.00%
Jane Street Group, LLC15,225$468.0K0.00%
Qube Research & Technologies Ltd14,700$452.0K0.01%
Maven Securities LTD12,500$389.0K0.04%
Tudor Investment Corp Et Al12,000$369.0K0.01%
Point72 Asset Management, L.P.10,000$307.0K0.00%
Virtu Financial LLC7,709$237.0K0.02%
Point72 Hong Kong Ltd2,576$79.0K0.01%
Bank of America Corp200$6.00K0.00%
Royal Bank of Canada32$1.00K0.00%

Sold out (0)

Institutions that held LENZ Therapeutics, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.

None.